To overcome preexisting immunity that cripples the adenovirus vectors used in gene therapy and vaccines, scientists at the University of Pittsburgh created a CRISPR-based system that briefly suppresses the genes that cause the problem. The method improved gene therapy uptake in mice and is being developed by startup SafeGen.